TIL,Instil Bio, Inc. | Healthcare

Healthcare

TIL

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Instil Bio, Inc.TIL

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.

The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Latest News >

Research Alert: CFRA Maintains Buy Opinion On Shares Of Alphabet Inc.

Mar 18, 2025

11:05 AM EDT, 03/18/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: GOOG announced its largest-ever acquisition, planning to acquire cloud security platform Wiz for $32B in cash, significantly above rumors of $23B a year earlier. The deal, expected to close in...

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading

Mar 18, 2025

11:07 AM EDT, 03/18/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were lower late Tuesday morning, declining 0.13% to 1,438.81 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies ( DBVT ) and Genfit ( GNFT ) , which rose 6.8% and 3.7% respectively....

What's Going On With REE Automotive Stock Tuesday?

Mar 18, 2025

REE Automotive Ltd. ( REE ) shares are moving lower on Tuesday after the company announced the pricing of a $27 million registered direct offering. What To Know: The company is pricing 6,376,631 shares at $4.25 per share. REE intends to use the net proceeds for working capital and general corporate purposes. What Else: REE entered into a non-binding memorandum...

Research Alert: CFRA Maintains Buy Opinion On Shares Of Alphabet Inc.

Mar 18, 2025

11:10 AM EDT, 03/18/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: GOOGL announced its largest-ever acquisition, planning to acquire cloud security platform Wiz for $32B in cash, significantly above rumors of $23B a year earlier. The deal, expected to close in...